GlassScriptPhysician profile
Moeid Riaz
NPI 1992347876
$8,431.56
in general payments reported to CMS, 2019-2025
56 companies · $2,577 in 2025
The $2,577 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $922 · 2022: $1,438 · 2023: $1,782 · 2024: $1,712 · 2025: $2,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,971 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,971.16 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $875.62 | 2021-2025 | Piqray, Kisqali |
| Merck Sharp & Dohme LLC | $739.47 | 2021-2025 | Keytruda, Welireg, Keytruda Qlex |
| Glaxosmithkline, LLC. | $698.48 | 2021-2025 | Jemperli, Ojjaara, Zejula |
| Astrazeneca Pharmaceuticals LP | $596.23 | 2021-2025 | Enhertu, Calquence, Lynparza |
| Gilead Sciences, INC. | $451.49 | 2021-2025 | Trodelvy |
| Janssen Biotech, INC. | $439.15 | 2021-2025 | Erleada, Darzalex, Rybrevant |
| Eisai INC. | $430.04 | 2022-2025 | |
| Abbvie INC. | $366.49 | 2024-2025 | |
| Tersera Therapeutics LLC | $299.76 | 2021-2025 | Zoladex, Xermelo, Quzyttir |
| Amgen INC. | $280.69 | 2021-2023 | Kyprolis |
| Daiichi Sankyo INC. | $265.05 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $236.47 | 2023-2025 | |
| Array Biopharma INC | $202.02 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Exelixis INC. | $197.58 | 2021-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $174.70 | 2021-2025 | Opdivo, Opdualag |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $157.31 | 2022-2025 | Alunbrig, Fruzaqla, Iclusig |
| Celgene Corporation | $134.38 | 2022-2024 | Reblozyl, Pomalyst |
| Ipsen Biopharmaceuticals, INC | $128.39 | 2021-2025 | Onivyde |
| Regeneron Healthcare Solutions, INC. | $123.52 | 2021-2024 | Libtayo |
| Genentech USA, INC. | $116.28 | 2023-2025 | Polivy, Tecentriq, Columvi |
| Genzyme Corporation | $103.08 | 2021-2025 | |
| Puma Biotechnology, INC. | $94.32 | 2021-2025 | |
| Lilly USA, LLC | $87.07 | 2022-2025 | Verzenio, Retevmo |
| Taiho Oncology, INC. | $81.64 | 2023-2025 | |
| Kite Pharma, INC. | $79.09 | 2021-2024 | Yescarta |
| Seagen INC. | $74.47 | 2021-2023 | Tukysa |
| Incyte Corporation | $69.46 | 2024-2025 | Monjuvi, Pemazyre |
| Kyowa Kirin, INC. | $68.74 | 2024-2025 | Poteligeo |
| Aveo Pharmaceuticals, INC. | $57.75 | 2022-2023 | Fotivda |
| Stemline Therapeutics INC. | $54.73 | 2023-2025 | Orserdu |
| Beigene USA, INC. | $51.86 | 2021 | |
| Karyopharm Therapeutics INC. | $51.64 | 2025 | Xpovio |
| Epizyme, INC. | $44.41 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $44.31 | 2023 | Darzalex, Tecvayli |
| Astellas Pharma US INC | $44.07 | 2023-2025 | Vyloy, Xospata |
| Sobi, INC | $39.97 | 2025 | |
| Apellis Pharmaceuticals, INC. | $38.88 | 2023-2024 | Empaveli |
| Springworks Therapeutics, INC. | $37.84 | 2024-2025 | Ogsiveo |
| Servier Pharmaceuticals LLC | $37.07 | 2025 | |
| Recordati_rare_diseases_inc. | $35.48 | 2025 | Enjaymo |
| Syndax Pharmaceuticals, INC. | $30.31 | 2025 | |
| G1 Therapeutics, INC. | $27.12 | 2022 | |
| Pharmacosmos Therapeutics INC. | $24.19 | 2024 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.14 | 2023 | Gilotrif |
| Beone Medicines USA, INC. | $23.14 | 2025 | Tevimbra |
| Legend Biotech USA INC. | $22.97 | 2025 | Carvykti |
| Blue Earth Diagnostics | $21.47 | 2025 | Posluma |
| Sanofi-Aventis U.S. LLC | $21.05 | 2021 | |
| Sumitomo Pharma America, INC. | $21.02 | 2025 | Orgovyx |
| Genmab U.S., INC. | $17.14 | 2023 | Tivdak |
| Pharmacyclics LLC, An Abbvie Company | $16.92 | 2022 | |
| Fresenius Kabi USA, LLC | $16.45 | 2025 | Stimufend |
| Geron Corporation | $15.16 | 2025 | Rytelo |
| Janssen Pharmaceuticals, INC | $14.21 | 2022 | |
| Blueprint Medicines Corporation | $14.19 | 2021 | |
| Pharmaand Gmbh | $13.08 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moeid Riaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.